This immunization guidance from the American Academy of Family Physicians (AAFP) addresses nonpregnant, immunocompetent adults 19 years and older and health care personnel. For other populations, see guidance from the American Academy of Pediatrics (for individuals 18 years and younger), Infectious Diseases Society of America (for individuals with immunocompromise), and American College of Obstetricians and Gynecologists (for pregnant individuals). Recommendations in this document are guided by the AAFP Adult Immunization Schedule. Where AAFP guidance differs from other organizations, the AAFP recommendation should be followed. AAFP immunization recommendations are reviewed and approved annually.
SUMMARY OF AAFP CLINICAL RECOMMENDATIONS
- All adults 19 years and older should receive an annual influenza vaccine and an updated COVID-19 vaccine.
- Adults 65 years and older should preferentially receive an enhanced influenza vaccine (high dose, adjuvanted, recombinant, or mRNA) when available, but vaccination should not be delayed if one is unavailable.
- Adults 65 years and older should receive two doses of the updated COVID-19 vaccine each season, with the first at month 0 and the second 6 months later.
- Adults 75 years and older and adults 50 to 74 years of age who are at increased risk should receive one dose of the respiratory syncytial virus (RSV) vaccine.
- Health care personnel should receive annual influenza and updated COVID-19 vaccination due to their repeated occupational exposure and contact with patients at high risk of severe disease.
WHY RESPIRATORY IMMUNIZATION IS RELEVANT THIS SEASON
Fall and winter respiratory season brings sharply elevated risk from three vaccine-preventable viruses: influenza, RSV, and SARS-CoV-2. In a Danish nationwide cohort of adults, RSV and influenza each accounted for substantial hospitalizations, with the risk concentrated in older adults and those with chronic cardiopulmonary disease, confirming that RSV burden in adults is comparable with that of influenza rather than incidental to it.2 US surveillance through the Respiratory Virus Hospitalization Surveillance Network (RESP-NET) tracks the three viruses and consistently identifies adults 65 years and older as being at highest risk for hospitalization and death.3
Younger adults with chronic conditions (eg, diabetes, obesity, chronic lung disease, cardiovascular disease) also experience substantial respiratory-related hospitalization; healthy younger adults contribute to community transmission.2,4 The recommendations in this document address all adults 19 years and older, not only those at highest risk.
Vaccine uptake remains well below where it should be, including in the highest-risk group. During the 2024–2025 influenza season, only 41.9% of adults 18 years and older and 64% of adults 65 years and older received an influenza vaccine.5 As of January 2026, 16.1% of adults had received a 2025–2026 COVID-19 vaccine, and 43.9% had received a 2025–2026 influenza vaccine.6 RSV vaccine–uptake rates among eligible older adults were similarly low. As of February 2026, 40.9% of adults 75 years and older and 30.9% of adults 50 to 74 years with high-risk conditions reported ever receiving an RSV vaccine.6
Immunization remains the most effective intervention to reduce severe respiratory illness.7 This document provides current AAFP recommendations, product guidance, and practical workflows for delivering vaccines efficiently in primary care.
INFLUENZA VACCINATION IN NONPREGNANT, IMMUNOCOMPETENT ADULTS 19 YEARS AND OLDER
Read the full article
Get immediate access, anytime, anywhere.
Choose a single article, issue, or full-access subscription.
Earn up to 14 CME credits per issue.
